Lower sales due to the pandemic but new rights issue secures continued international expansion
First quarter
Result after tax came in at SEK -8.9 (0.7) million.
Earnings per share, basic and diluted, were SEK -0.06 (0.01).
Cash and cash equivalents were SEK 21.4 (33.9) million.
Significant events in Q1
Enzymatica s sales during the quarter declined compared with the corresponding period in 2020 due to the effects of the pandemic, which essentially reduced the cold remedy market by 50 percent, both in Sweden and in other markets.
Enzymatica announced on March 22 that sales for 2021 could be lower than sales for 2020, which totaled SEK 111 million, because of the impact of the pandemic on the cold remedy market. The Board of Directors has therefore decided to raise SEK 59 million through a rights issue to fund the company s long-term initiatives and to meet working capital needs for the next 12 months.
Positive operating result and almost doubled sales for the fourth quarter
News provided by
Share this article
Q4
Result after tax came in at SEK -0.3 (-5.3) million.
Earnings per share, basic and diluted, were SEK 0.00 (-0.04).
Cash and cash equivalents were SEK 24.0 (29.3) million.
Full year
Result after tax came in at SEK -13.2 (-41.0) million.
Earnings per share, basic and diluted, were SEK -0.09
(-0.29).
Significant events during the quarter
Enzymatica continued its international expansion. Sanofi launched ColdZyme® in France and Italy under its established cold remedy brands Physiomer® Stop Virus and Zerinol® Virus Defence.
Enzymatica signed an agreement with MS Pharma for MENA - the Middle East and North Africa, and also expanded the agreement with STADA for Russia, Poland, Ukraine and the CIS countries (Commonwealth of Independent States - formerly Soviet republics),
Positive operating result and almost doubled sales for the fourth quarter finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.